Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 Trial | Zendy

Clémence Basse | Zendy; Claire Morel | Zendy; Céline Callens | Zendy; Gaëlle Pierron | Zendy; Vincent Servois | Zendy; Anne VincentSalomon | Zendy; Aude Jobard | Zendy; Marie Alt | Zendy; Francesco Ricci | Zendy; Delphine Loirat | Zendy; MariePaule Sablin | Zendy; Marie Bretagne | Zendy; Mathilde SaintGhislain | Zendy; S. Hescot | Zendy; Anthony Gonçalvès | Zendy; Olivier Trédan | Zendy; Coraline Dubot | Zendy; Céline Gavoille | Zendy; JeanPierre Delord | Zendy; Mario Campone | Zendy; Nicolás Isambert | Zendy; Lisa Belin | Zendy; Ivan Bièche | Zendy; Maud Kamal | Zendy; Christophe Le Tourneau | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 Trial

Author(s) -

Clémence Basse,

Claire Morel,

Céline Callens,

Gaëlle Pierron,

Vincent Servois,

Anne VincentSalomon,

Aude Jobard,

Marie Alt,

Francesco Ricci,

Delphine Loirat,

MariePaule Sablin,

Marie Bretagne,

Mathilde SaintGhislain,

S. Hescot,

Anthony Gonçalvès,

Olivier Trédan,

Coraline Dubot,

Céline Gavoille,

JeanPierre Delord,

Mario Campone,

Nicolás Isambert,

Lisa Belin,

Ivan Bièche,

Maud Kamal,

Christophe Le Tourneau

Publication year - 2018

Publication title -

jco precision oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.405

H-Index - 22

ISSN - 2473-4284

DOI - 10.1200/po.18.00048

Subject(s) - medicine , oncology , pten , clinical trial , breast cancer , targeted therapy , tamoxifen , precision medicine , cancer , pathology , pi3k/akt/mtor pathway , apoptosis , biochemistry , chemistry

Precision medicine trials constitute a precious source of molecular data with prospective clinical annotations allowing the exploration of patients' subpopulations according to specific clinical or biological questions. Using the SHIVA01-the first randomized trial comparing molecularly targeted therapy on the basis of tumor molecular profiling versus conventional chemotherapy in metastatic cancer patients who failed standard of care therapy-annotated database, we report cases of patients treated in the trial with targeted therapy who experienced an objective response or prolonged disease stabilization in light of patients' molecular alterations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research